Rapport Therapeutics (NASDAQ:RAPP) Director James Healy Purchases 44,032 Shares

Rapport Therapeutics (NASDAQ:RAPP) Director James Healy purchased 44,032 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was acquired at an average cost of $24.52 per share, with a total value of $1,079,664.64. Following the completion of the acquisition, the director now directly owns 40,851 shares of the company’s stock, valued at $1,001,666.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Rapport Therapeutics Trading Down 6.8 %

Shares of Rapport Therapeutics stock opened at $23.30 on Thursday. Rapport Therapeutics has a 12 month low of $18.00 and a 12 month high of $27.11.

Wall Street Analyst Weigh In

Several analysts have recently commented on RAPP shares. Jefferies Financial Group began coverage on shares of Rapport Therapeutics in a research note on Tuesday. They set a “buy” rating and a $35.00 price target on the stock. Stifel Nicolaus began coverage on Rapport Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 target price for the company. Finally, TD Cowen initiated coverage on Rapport Therapeutics in a report on Tuesday. They issued a “buy” rating on the stock.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.